These agents differ in structure and are generally classified ... size table Regarding the anti-PD-1 antibodies, the fully human nivolumab (Bristol-Myers Squibb) and the humanised pembrolizumab ...

With 44,000 new diagnoses each year, non-small cell lung cancer is the second most frequent neoplasm in Italy after breast ...

Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

This new subcutaneous formulation of nivolumab will help extend the reach ... and managing our cost structure. We have entered 2025 with a stronger foundation to deliver on our long-term growth ...

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.

This is based on data from the CheckMate 451 trial [phase 3; NCT02538666] where nivolumab [Opdivo] did not lead to improved ... to consider the logistics of these therapies, developing the structure ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...

The CHMP recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).

This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab ...